When Reuters Is Already There, The Edge Is Gone: FDA-Litigation Narratives Turn Into Noise Fast
The Opportunity
There is no opportunity here in the alpha sense, and the system correctly flags it as edge-decaying. Upstream lifecycle is spreading with explicit Tier-1 presence, which is the whole point: once a regulatory or litigation narrative has broad pickup, the market is no longer trading on information asymmetry but on interpretation and positioning. 7A classifies this as FADE and we treat it as AVOID, even though a sector proxy exists (XBI). The direction display is MIXED because the only honest posture after edge decay is non-directional: you are late.
The Timing
The tape is Bearish 62 with high crosswind risk 72, which tempts people to press generic shorts. Do not confuse a supportive macro feel with a still-open information window. The edge window is explicitly closing and propagation posture is catalytic, meaning the story is already in the market's bloodstream. The only scenario where this becomes relevant again is if a genuinely new primary artefact appears that changes the factual set (not just the commentary), restarting the clock.
The Evidence
Upstream evidence indicates Tier-1 pickup (including reuters.com and nytimes.com ) alongside broad multi-source dissemination, which is why the information-edge score is low and lifecycle is spreading. No specific URLs were hydrated in this cycle for the Tier-1 items, so treat this as a regime classification: it is widely known enough that the edge is DECAYING by construction.